I am a
Home I AM A Search Login

Papers of the Week


Papers: 28 Oct 2023 - 3 Nov 2023


2023 Oct 26


N Engl J Med


37888917


389


17

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

Authors

Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S

Abstract

Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis.